Abstract Number: 2102 • ACR Convergence 2022
Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
Background/Purpose: An accurate target in Systemic Lupus Erythematosus (SLE) Treat to Target strategies has been challenging over the past years. Recently, a new definition of…Abstract Number: 2226 • ACR Convergence 2022
Accelerated Aging Based on Blood DNA Methylation in SLE Participants Compared to Healthy Controls
Background/Purpose: Epigenetic clocks based on DNA methylation in blood have been shown to correlate with biological aging and predict adverse health outcomes, including mortality. Accelerated…Abstract Number: 0064 • ACR Convergence 2022
Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease that can damage multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular…Abstract Number: 0183 • ACR Convergence 2022
LupusConnect™: A 24/7 Online Lupus Support Community
Background/Purpose: A Lupus Foundation of America (LFA) National Needs Assessment Survey in 2015 with 3402 lupus patients and caregivers found that the number one need…Abstract Number: 0331 • ACR Convergence 2022
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
Background/Purpose: SLE is characterized by autoantibody production. The most common lupus-specific serology is the anti-dsDNA antibody (anti-DNA). Traditionally, anti-DNA is measured by an enzyme immunoassay…Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…Abstract Number: 0370 • ACR Convergence 2022
Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is often associated with symptoms such as fatigue, pain, and depressive symptoms that contribute to poor health-related quality of…Abstract Number: 0635 • ACR Convergence 2022
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Background/Purpose: Anti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). ANA may become positive years in advance of…Abstract Number: 0655 • ACR Convergence 2022
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…Abstract Number: 0715 • ACR Convergence 2022
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
Background/Purpose: Data on immunogenicity and safety of COVID-19 vaccination strategies exist for the general population, however, such data are limited for immunocompromised people including those…Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…Abstract Number: 0980 • ACR Convergence 2022
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…Abstract Number: 0997 • ACR Convergence 2022
Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Background/Purpose: Attempts to stop glucocorticoids among Systemic Lupus Erythematosus(SLE) patients in long term remission have been successful. Continuing other immunosuppressive (IS) agents indefinitely is currently…Abstract Number: 1141 • ACR Convergence 2022
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology and heterogenous symptomatology which has been recently dissected using…Abstract Number: 1352 • ACR Convergence 2022
Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
Background/Purpose: Mental health (MH) problems are prevalent in adolescents with childhood-onset lupus (cSLE), with cross-sectional studies estimating prevalences of 20-60% for depression symptoms and 20-40%…
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 150
- Next Page »